Delivering genetic material is a key challenge in gene therapy.
Invitation image created by Kstudio
One big challenge for gene therapies is delivering DNA or RNA safely to cells inside patients' bodies. New nanoparticles could be an improvement over the current standard – repurposed viruses.
By 2030, the Blue Economy will be worth $3 trillion. And the UK is well placed to capture a slice of this lucrative market, if it meets the challenges involved with innovation and ambition.
Do androids smell electric roses?
From spinach that can detect explosives to vegetarian meat, biological technology has the potential to change the world.
People get suspicious when ethically fraught science is discussed behind closed doors.
DNA image via www.shutterstock.com.
A recent closed meeting about building synthetic genomes raised suspicions about just what scientists were planning, away from the public eye.
A rush and a push and the land is ours …
Monsanto an other biotech companies got caught short in the 1990s. But since then, the GM argument has been moving in their direction.
Why are half of European Union members opting out of GMO crops? Hint: it's not about food and environmental safety.
The accuracy of gene editing will be the deciding factor in the success of current technology.
Genes by Shutterstock
A toddler from London has had gene therapy for leukaemia and it seems to have worked. But why have breakthroughs taken so long?
Bashing drugmakers can be an easy way to score political points.
Clinton, who named drug companies among her enemies in this week's debate, is pushing populist-inspired policies that could hamper the flow of new medicines.
New EU rules on GM attempt to unblock logjam that has hung over the technology in the region for most of this century. To work, anti-GM member states and Big Biotech will need to cooperate.